AIM
In recent years, a number of new disease modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) have been approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). These have greatly expanded the treatment options for patients with MS and have included the first oral DMTs (dimethyl fumarate, fingolimod, and teriflunomide), as well as alemtuzumab.
This study evaluated the health technology assessment (HTA) appraisals for these DMTs to identify any trends or future opportunities in MS.
RESULTS
A total of 19 submissions were identified, all of which included a placebo-controlled trial, and all except dimethyl fumarate also included a head-to-head trial against one of the beta-interferons but not any other therapies. 
Payer critique
Alemtuzumab: Lack of head-to-head trials with newer therapies (e.g. natalizumab and fingolimod) (NICE, SMC); lack of transparency within the MTC and subgroup analyses conducted (NICE, SMC); heterogeneity in the trial populations for indirect comparisons with fingolimod and natalizumab (NICE, SMC); open-label study was identified as a source of bias (NICE).
Dimethyl fumarate: Claims of superiority vs. ABCR and non-inferiority vs. fingolimod not adequately supported (PBAC); no head-to-head trial and lack of long-term data for SDP and safety (CDEC).
Fingolimod: Weaknesses in indirect comparisons and heterogeneity of trial populations (NICE); ICER underestimated (PBAC); limitations in model and uncertainty in input parameters, limitation of ARR in predicting long-terms outcomes (CDEC).
Teriflunomide: Head-to-head comparisons limited to one IFN-β formulation (IQWiG); no relevant differences in morbidity and QoL (IQWiG); clinical benefits do not justify cost (TLV); scarcity of head-to-head trial (SMC); 6-month SDP improvement not observed (NICE).
METHODS
HTA appraisals for alemtuzumab, dimethyl fumarate, fingolimod, and teriflunomide from NICE (England), SMC (Scotland), CDEC (Canada), PBAC (Australia), HAS (France), TLV (Sweden) and IQWiG (Germany) were identified. Recommendations, reasoning, and the supporting clinical and economic evidence were extracted.
CONCLUSION
• Due to the changing treatment landscape and the population included in MS trials, it is clear that placebo-controlled or interferon-controlled trials do not generate the required evidence. The inclusion of beta-interferon trials in indirect comparisons is becoming less suitable for the evaluation of new MS treatments
• Future HTA submissions will need to take into account the need to demonstrate superiority over comparators, and manufacturers and regulators will need to work together to develop new and reliable measures that can evaluate MS symptoms and impairments in the context of DMTs
